Danielle E. Arnold
National Institutes of Health
Genetic enhancementInternal medicineCalcineurinImmunologyT cellHematopoietic stem cell transplantationChronic granulomatous diseaseInflammatory bowel diseasePrimary immunodeficiencyDiseaseMyeloidGraft-versus-host diseaseAutoimmunityB-cell acute lymphoblastic leukemiaPopulationCD19-specific chimeric antigen receptorTransplantationSubcutaneous immunoglobulinCancer researchMedicineImmune system
15Publications
4H-index
132Citations
Publications 14
Newest
#1Danielle E. Arnold (NIH: National Institutes of Health)H-Index: 4
#2Deepak Chellapandian (Center for Cell and Gene Therapy)
Last. Jennifer W. Leiding (USFSP: University of South Florida St. Petersburg)H-Index: 11
view all 3 authors...
Recently, primary immune regulatory disorders have been described as a subset of inborn errors of immunity that are dominated by immune mediated pathology. As the pathophysiology of disease is elucidated, use of biologic modifiers have been increasingly used successfully to treat disease mediated clinical manifestations. Hematopoietic cell transplant (HCT) has also provided definitive therapy in several PIRDs. Although biologic modifiers have been largely successful at treating disease related m...
Source
#1Trusha Patel (UPenn: University of Pennsylvania)H-Index: 7
#2Sarah E. Henrickson (UPenn: University of Pennsylvania)H-Index: 29
Last. Judith R. Kelsen (UPenn: University of Pennsylvania)H-Index: 21
view all 21 authors...
ABSTRACT Background Mutations in ITCH, which encodes an E3 ubiquitin-protein ligase, can result in systemic autoimmunity and immunodeficiency. The clinical phenotype and mechanism of disease have not been fully characterized, resulting in a paucity of therapeutic options for this potentially fatal disease. Objective We aimed to: (1) expand the understanding about the phenotype of human ITCH deficiency (2) further characterize the associated immune dysregulation and (3) report the first successfu...
Source
#1Danielle E. Arnold (Children's Hospital of Philadelphia)H-Index: 4
#2Derek MacMath (UPenn: University of Pennsylvania)
Last. Nancy Bunin (Children's Hospital of Philadelphia)H-Index: 54
view all 8 authors...
Abstract TCRαβ/CD19-depleted HCT has been used with excellent outcomes in pediatric patients with hematologic malignancies, and several studies have demonstrated rapid immune reconstitution in the nonmalignant setting. However, immune recovery following TCRαβ/CD19-depleted hematopoietic cell transplantation (HCT) for malignancy remains incompletely elucidated. Furthermore, the majority of studies to date have used haploidentical and matched unrelated donors. Here we report results of immune reco...
Source
#1Danielle E. Arnold (NIH: National Institutes of Health)H-Index: 4
#2Jennifer Heimall (NIH: National Institutes of Health)H-Index: 22
Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency due to mutations in any of the critical subunits of the phagocyte NADPH oxidase complex, resulting in impaired oxidase activity of neutrophils, monocytes, and tissue macrophages. It is characterized by increased susceptibility to recurrent and severe infections with a narrow pathognomonic spectrum of bacteria and fungi, granuloma formation, and inflammatory disease, primarily of the gastrointestinal tract, lungs, and li...
Source
#1Benjamin T Prince (OSU: Ohio State University)H-Index: 5
#2Beth K Thielen (UMN: University of Minnesota)H-Index: 9
Last. Steven M. Holland (NIH: National Institutes of Health)H-Index: 114
view all 10 authors...
Chronic granulomatous disease (CGD) is a rare but serious primary immunodeficiency with varying prevalence and rates of X-linked and autosomal recessive disease worldwide. Functional defects in the phagocyte nicotinamide adenine dinucleotide phosphate oxidase complex predispose patients to a relatively narrow spectrum of bacterial and fungal infections that are sometimes fastidious and often difficult to identify. When evaluating and treating patients with CGD, it is important to consider their ...
Source
#1Danielle E. Arnold (Children's Hospital of Philadelphia)H-Index: 4
#2Shannon L. Maude (UPenn: University of Pennsylvania)H-Index: 4
Last. Jennifer Heimall (UPenn: University of Pennsylvania)H-Index: 22
view all 6 authors...
Twenty-eight patients were maintained on subcutaneous immunoglobulin replacement for persistent B-cell aplasia and agammaglobulinemia following CD19-targeted chimeric antigen receptor T-cell therapy for B-cell lymphoblastic leukemia. Patients were transitioned from intravenous to subcutaneous immunoglobulin replacement at a median of 11.5 months (range, 4-20). Increasing serum IgG level was significantly associated with a lower rate of sinopulmonary infection (P = 0.0072). The median serum IgG l...
7 CitationsSource
#1Rebecca A. Marsh (Cincinnati Children's Hospital Medical Center)H-Index: 33
#2Jennifer W. Leiding (USFSP: University of South Florida St. Petersburg)H-Index: 11
Last. Elizabeth M. Kang (NIH: National Institutes of Health)H-Index: 27
view all 54 authors...
Introduction Inflammatory bowel disease (IBD) affects approximately 1/3 of patients with chronic granulomatous disease (CGD). Comprehensive investigation of the effect of allogeneic hematopoietic cell transplantation (HCT) on CGD IBD and the impact of IBD on transplant outcomes is lacking.
17 CitationsSource
#1David T. Teachey (UPenn: University of Pennsylvania)H-Index: 56
#2Danielle E. Arnold (Children's Hospital of Philadelphia)H-Index: 4
Source
#1Danielle E. Arnold (Children's Hospital of Philadelphia)H-Index: 4
#2Alix E. Seif (UPenn: University of Pennsylvania)H-Index: 26
Last. Jennifer Heimall (UPenn: University of Pennsylvania)H-Index: 22
view all 6 authors...
7 CitationsSource
#1Danielle E. Arnold (Children's Hospital of Philadelphia)H-Index: 4
#2Colleen Callahan (Children's Hospital of Philadelphia)H-Index: 19
Last. Jennifer Heimall (Children's Hospital of Philadelphia)H-Index: 22
view all 5 authors...
1 CitationsSource